• Trump Pence News
    Trump Pence News
  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Тelegram iGaming Software
    Тelegram iGaming Software
  • Weather: Disaster Alerts
    Weather: Disaster Alerts

Special News Reports

+ Larger Font | + Smaller Font

feed-image RSS

Globe NewsWire News Distribution Service

GlobeNewswire and NASDAQ form a single worldwide news distribution service with expertise in multiple continents, helping public and private companies communicate with media and investors in local languages. Publicly traded companies can now seamlessly address their regulatory disclosure requirements in markets throughout the world. Learn more about GlobeNewsWire.com here.

RobinsPost.com has partnered with Globe Newswire to bring you the latest industry information from top companies. This partnership will bring value and help consumers to receive the best product and news data on the web. The partnership was formed on September 14th, 2015.

NASDAQ YouTube Channel


HMS Holdings Corp. Reports Fourth Quarter and Full-Year 2016 Results

Q4 GAAP EPS of $0.13 and Adjusted EPS of $0.20 Per Diluted Share / Full-Year 2016 GAAP EPS of $0.43 (+53.6% YOY) and Adjusted EPS of $0.75 (+31.6% YOY) Per Diluted ShareQ4 Revenue of $128.1 Million / Full-Year 2016 Revenue Increased 4.6% YOY to a Record $496.0 MillionRecord Q4 Commercial Health Plan Revenue of $64.3 Million / Full-Year 2016 Commercial Health Plan Revenue of $234.7 Million was 15.6% Higher YOYQ4 Share Repurchases of ~$20.5 Million7-9% Total Revenue Growth Projected for 2017, Including High Teens Commercial Health Plan GrowthIRVING, Texas, Feb. 24, 2017 (GLOBE NEWSWIRE) -- HMS Holdings Corp. (NASDAQ:HMSY) today announced financial results for the fourth quarter and full-year 2016. Net income for the quarter ended December 31, 2016 was $11.0 million or $0.13 per diluted share, compared to net income of $13.5 million or $0.16 per diluted share in the third quarter of 2016 and $8.7 million or $0.10 per diluted share in the prior year fourth quarter. Adjusted EPS in the quarter was $0.20 per diluted share, compared to adjusted EPS of $0.24 per diluted share in the third quarter of 2016 and adjusted EPS of $0.19 per diluted share in the prior year fourth quarter. Net income and adjusted EPS in the third quarter of 2016 both included tax benefits of approximately $6.2 million or $0.07 per diluted share for certain prior open years’ Research and Development (“R&D”) credits and domestic manufacturing deductions recognized in the quarter.For the full-year ended December 31, 2016, net income was $37.6 million or $0.43 per diluted share, compared to $24.5 million or $0.28 per diluted share in the prior year – an increase of $0.15 or 53.6%. Adjusted EPS for the full-year 2016 was $0.75 per diluted share, compared to $0.57 per diluted share in full-year 2015 - an increase of $0.18 per diluted share or 31.6%.Total revenue in the fourth quarter was $128.1 million, compared to total revenue of $124.6 million in the third quarter of 2016 and $128.5 million in the prior year fourth quarter. For the full-year 2016, total revenue increased 4.6% to a record $496.0 million, including $18.8 million of Medicare RAC revenue, compared to total revenue for the full-year 2015 of $474.2 million, which included $20.5 million of Medicare RAC revenue.“2016 was a year of solid growth in total revenue, operating income and adjusted EPS. Adjusted EBITDA also increased, overall profitability and margins improved, operating cash flow remained strong and we acquired a care management platform - which was our first step in building out a new vertical to complement our historically strong cost containment product suite,” said Bill Lucia, Chairman and CEO. “We enter the new year with momentum as fourth quarter health plan revenue of $64.3 million was the second consecutive record quarterly total, though not quite enough to meet our full-year growth target. Additionally, sales which closed during the second half of 2016 and will become revenue generating over the next few months; the run rate benefit of business implemented throughout last year; ongoing product yield improvement initiatives; and a robust pipeline of potential sales we expect to close in the early part of this year each contribute to our view of expected 2017 growth. As a result, we are projecting a high teens increase in year-over-year health plan revenue," Lucia concluded.Revenue in the fourth quarter of $127.4 million, excluding Medicare RAC, was approximately 7.2% higher than the prior year fourth quarter. Commercial health plan revenue in the quarter was a record $64.3 million, a 10% increase compared to $58.5 million in the prior year fourth quarter and 8.6% higher than the third quarter of 2016. State government revenue was $57.7 million in the fourth quarter, a 5.9% increase compared to $54.5 million in the prior year fourth quarter and 8.9% higher than the third quarter of 2016. Federal (excluding Medicare RAC) and Other revenue was $5.3 million in the fourth quarter, a $0.5 million decrease compared to the prior year fourth quarter and a $0.5 million decrease compared to the third quarter of 2016. Medicare RAC revenue in the fourth quarter of 2016 was $0.7 million, compared to $9.7 million in the prior year fourth quarter and $5.8 million in the third quarter of 2016.On a full-year basis, commercial health plan revenue was $234.7 million, a 15.6% increase compared to $203.1 million in 2015; state government revenue was $219.1 million, a 3.1% decrease compared to $226.1 million in 2015; Federal (excluding Medicare RAC) and Other revenue was $23.3 million, a decrease of $1.3 million or 5.3% compared to 2015; and Medicare RAC revenue was $18.8 million, an 8.0% decrease compared to $20.5 million in 2015.Coordination of Benefits (“COB”) revenue, which continues to be our largest product line across both the state government and commercial health plan businesses, was $95.0 million in the fourth quarter of 2016 compared to $87.1 million in the prior year fourth quarter and $86.3 million in the third quarter of 2016. COB accounted for 74.2% of total revenue in the fourth quarter, compared to 67.8% in the prior year fourth quarter and 69.3% in the third quarter of 2016. For the full-year, COB revenue was $353.9 million, a 4.8% increase compared to $337.6 million in 2015.Payment integrity (“PI”) revenue (excluding Medicare RAC) was $32.4 million in the fourth quarter, a $0.7 million or 2.2% increase compared to the prior year fourth quarter and a $0.1 million or 0.3% decrease from the third quarter of 2016. For the full-year, PI revenue was $123.3 million, a 6.2% increase compared to $116.1 million in 2015. "The leveragability and cash flow generation inherent in our operating model was evident throughout 2016, but particularly so in the fourth quarter which included adjusted EBITDA of $32.2 million, operating cash flow of $34.3 million and a 14.6% operating margin," said Jeff Sherman, CFO. “Available cash at year-end of ~$176 million was significantly higher than the prior year end, even after our third-quarter acquisition of Essette and share repurchases in the fourth quarter of approximately $20.5 million. Our strong balance sheet and expected operating cash flow of $90–110 million for 2017 position the Company well for additional acquisitions, planned investments in big data solutions and our IT infrastructure, internal product innovation activities and other growth initiatives," added Sherman.For additional information about the Company’s fourth quarter and full-year 2016 financial results and the Company’s 2017 guidance, see the Q4 and Full-Year 2016 Investor Presentation which is available on the Company’s website at http://investor.hms.com/events.cfm.Webcast and Conference Call Information

Read more...

YPO Launches Second-Annual Innovation Week in May 2017

DALLAS, 23 February 2017 - For the second consecutive year, YPO will host Innovation Week, a series of more than 70 events around the world designed to bring together the world's most dynamic innovators for a chance to connect, challenge conventional thinking and gain actionable, applicable insight.YPO, the world's premier chief executive networking organization, will host innovation events all across the globe including Melbourne, Tel Aviv, New York, Toronto, Silicon Valley, Hong Kong and more the week of 8-12 May 2017. The mission of YPO Innovation Week is to drive innovation across a diverse range of industries through signature events, live two-way interactive video casts and livestream events across more than 30 countries."Every business leader needs to focus on innovation to grow and thrive," says YPO Innovation Week Chair Keith Alper, Founder and CEO of GenieCast. "YPO Innovation Week will provide hundreds of opportunities for members to learn from each other and from the most well respected global innovators, disrupters, inventors to help integrate innovation at the most strategic level across all businesses. Combining research, technology and business leadership, Innovation Week is the one place where the world's most innovative companies share their inspiration and insights."YPO Innovation Week offers YPO business leaders with learning and networking opportunities to infuse innovation into their companies, form strategic partnerships, and positively affect their businesses and the communities in which they work. YPO leaders will be able to leverage new partnerships in innovation, infuse innovation into the heart of their company culture, and convert ideas into actionable plans.The week will feature idea jams, workshops, live-streamed panels, insider company tours, global conference calls, TED-style presentations and debates. Highlights include:Igniting Innovation in Australia, 8-9 May 2017, Melbourne, Australia: Kicking of Innovation Week, this event will feature top growth innovators and their best practices on how to ignite an innovation culture within business and understand the common forces that will impact the future.Silicon Summit 2017, 8-10 May 2017, Silicon Valley, California, USA: Leading entrepreneurs and venture capitalists at the ground zero of modern invention will examine how technology can advance cutting-edge concepts.InnovNation: Israel Innovation Experience, 9-11 May 2017, Tel Aviv, Israel: Entrepreneurial innovators will explore the questions every startup has and how communities - like Israel with the highest concentration of startups in the world - can work together to build the next great revolution.The Art of the Start - Accelerating Your Startup Growth, 10-11 May 2017, Toronto, Ontario, Canada: Trailblazers and experts from the trenches will share their insights about how to optimize the speed and trajectory of a startup for success at every level.Grand Finale for YPO Innovation Week, 11-12 May 2017, New York, New York, USA: World-class experts in finance, hospitality and technology will close the week with in-depth sessions and a "shark tank" style pitch contest.Disruptive Business Models in Asia, 12 May 2017, Hong Kong, China:  the grand finale of YPO Innovation Week in Asia as members come together at the Hong Kong Stock Exchange to ring the closing gong.
 
For more information, visit the YPO Innovation Week website.             ###             ABOUT YPOThe premier leadership organization of chief executives in the world.YPO is the global platform for chief executives to engage, learn and grow. YPO members harness the knowledge, influence and trust of the world's most influential and innovative business leaders to inspire business, personal, family and community impact.Today, YPO empowers more than 24,000 members in more than 130 countries, diversified among industries and types of businesses. Altogether, YPO member-run companies employ more than 15 million people and generate USD6 trillion in annual revenues.Leadership. Learning. Lifelong. For more information, visit YPO.org.Contact:
YPO
Linda Fisk
Office: +1 972 629 7305 (United States)
Mobile: +1 972 207 4298
This email address is being protected from spambots. You need JavaScript enabled to view it.
">This email address is being protected from spambots. You need JavaScript enabled to view it.

Read more...

Global Myocardial Infarction Treatment Market will reach $1726.3 million by 2022: Zion Market Research

Sarasota, FL, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Myocardial Infarction Treatment Market by Product type (Antiplatelet agents, Glycoprotein IIb/IIIa inhibitors, Antithrombotic agents, Beta-adrenergic blockers, Vasodilators, Angiotensin-Converting Enzyme (ACE) inhibitors, Angiotensin-Receptor blockers, Analgesics, Thrombolytics); Distribution channel (Hospitals, Hospital Pharmacies, Drug Stores and Online Drug Stores); and Region: Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2022”. According to the report, global Myocardial Infarction Treatment Market was valued at approximately USD 1206.5 million in 2016 and is expected to generate revenue of around USD 1726.3 million by end of 2022, growing at a CAGR of around 6.1% between 2017 and 2022. Myocardial infarction or heart attack is caused due to blockage in the supply of oxygen-rich blood to heart muscles, resulting in permanent heart muscle injury and death of cells. The blockage is due to atherosclerosis, a process in which the plaque (fatty patches) is formed on the inside wall of the coronary artery or one of its smaller branches. If the plaque is ruptured, the blood clot is formed inside the artery blocking the blood flow. People with risk factors such as smoking, dyslipidemia, diabetes are more prone to myocardial infarction.
Browse through 29 Market Tables and 31 Figures spread through 110 Pages and in-depth TOC on “Global Myocardial Infarction Treatment Market: By product, Distribution, Type, Size, Share, Analysis, Segment and Forecast 2016 – 2022”.Request Free Sample copy of Myocardial Infarction Treatment Market Report @ https://www.zionmarketresearch.com/sample/myocardial-infarction-treatment-marketGlobal Myocardial Infarction Treatment market is primarily driven by growing incidences of cardiovascular diseases and changes in lifestyle. Other major driving factors are risk factors such as obesity, hypertension, diabetes, reduced physical activity, and rise in a number of smokers. As per WHO, the risk of myocardial infarction is increased in smokers than non-smokers. However, the high price of drug research and development and stringent regulatory policies coupled with high cost of clinical trials may pose the challenge to myocardial infarction treatment market. Nevertheless, increase in acceptance of newer treatment technologies by emerging nations and technology breakthroughs are expected to act new avenues for myocardial infarction treatment market in near future.
 
The Myocardial Infarction Treatment market is segmented on the basis of different product type including Antiplatelet agents, Glycoprotein IIb/IIIa inhibitors, Antithrombotic agents, Beta-adrenergic blockers, Vasodilators, Angiotensin-Converting Enzyme (ACE) inhibitors, Angiotensin-Receptor blockers, Analgesics, Thrombolytics. Analgesics and antiplatelet agent segments are expected to grow at the fastest rate during the forecast period.
Browse the full "Myocardial Infarction Treatment Market by Product type (Antiplatelet agents, Glycoprotein IIb/IIIa inhibitors, Antithrombotic agents, Beta-adrenergic blockers, Vasodilators, Angiotensin-Converting Enzyme (ACE) inhibitors, Angiotensin-Receptor blockers, Analgesics, Thrombolytics); Distribution channel (Hospitals, Hospital Pharmacies, Drug Stores and Online Drug Stores); and Region: Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2022" report at https://www.zionmarketresearch.com/report/myocardial-infarction-treatment-market
The myocardial infarction treatment market is segmented based on distribution channel into Hospitals, Hospital Pharmacies, Drug Stores and Online Drug Stores. Based on geography, the myocardial infarction treatment market is segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa.
North America represents developed regional markets for myocardial infarction treatment market and is expected to see the rapid growth in the years to come. The U.S. is by far the leading myocardial infarction treatment market by country in North America. The U.S. market is expected to grow at the highest CAGR during the forecast period. This growth is mainly due to the growing incidences of cardiovascular diseases, obesity, and smokers. Moreover, other risk factors such as hypertension, diabetes, and dyslipidemia are very high in this region which promotes the growth of myocardial infarction treatment market. Inquire more about this report @ https://www.zionmarketresearch.com/inquiry/myocardial-infarction-treatment-marketEurope was the second largest regional market and is expected to show significant growth in the years to come. This growth is mainly due to increase in a number of patients diagnosed with hypertension. As per WHO, cardiovascular disease (CVD) causes more than half of all deaths across the European region.Asia-Pacific is expected to witness the fastest growth in the near future. Increasing geriatric population is the major driving factor along with lifestyle changes, physical inactivity and increasing prevalence of diabetes. However increased awareness of such life-threatening diseases may impact the market share.Request customized copy of report @ https://www.zionmarketresearch.com/custom/1084Latin America and Middle East & Africa market will be potential market due to increased awareness and adoption of newer myocardial infarction treatment. Thus, all the aforementioned parameters are expected to propel the market growth in this region.Some of the key players in Myocardial Infarction Treatment market include Bayer, Novartis, Daiichi Sankyo Company Limited, Boehringer Ingelheim GmbH, Sandoz, Astrazeneca, Janssen Biotech, Inc., Merck & Co. Inc., Sanofi, Pfizer Inc. among others.For more inquiry contact our sales team @ This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.This report segments the global Myocardial Infarction Treatment market as follows:Myocardial Infarction Treatment Market: By Product TypeAntiplatelet agentsGlycoprotein IIb/IIIa inhibitorsAntithrombotic agentsBeta-adrenergic blockersVasodilatorsAngiotensin-Converting Enzyme (ACE) inhibitorsAngiotensin-Receptor blockersAnalgesicsThrombolyticsMyocardial Infarction Treatment Market: By Distribution Channel
HospitalsHospital PharmaciesDrug StoresOnline Drug StoresMyocardial Infarction Treatment Market: Regional Segment Analysis
North AmericaU.S.EuropeUKFranceGermany Asia PacificChinaJapanIndiaLatin AmericaBrazilThe Middle East and AfricaRelated Reports:
Melanoma Drugs Market: https://www.zionmarketresearch.com/report/melanoma-drugs-market
Osteoporosis Drugs Market: https://www.zionmarketresearch.com/report/osteoporosis-drugs-market
Medical Device Coatings Market: https://www.zionmarketresearch.com/report/medical-device-coatings-market
Drug Discovery Informatics Market: https://www.zionmarketresearch.com/report/drug-discovery-informatics-market
General Anxiety Disorder Market: https://www.zionmarketresearch.com/report/general-anxiety-disorder-market
About Us:
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research
Follow Us Twitter: https://twitter.com/zion_researchContact Us: Joel John 4283, Express Lane, Suite 634-143, Sarasota, Florida 34249, United States Tel: +49-322 210 92714 USA/Canada Toll-Free No.1-855-465-4651 Email: This email address is being protected from spambots. You need JavaScript enabled to view it. Website: https://www.zionmarketresearch.com

Read more...

Accelerate Diagnostics Receives FDA Marketing Authorization for the Accelerate Pheno™ System and Accelerate PhenoTest™ BC Kit

TUCSON, Ariz., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (Accelerate) today announced that the U.S. Food and Drug Administration has granted the de novo request to market the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for identification and antibiotic susceptibility testing of pathogens directly from positive blood culture samples. The blood culture kit is indicated for susceptibility testing of specific pathogenic bacteria commonly associated with bacteremia, the leading cause of sepsis.
The Centers for Disease Control and Prevention estimate at least 2 million people each year are infected with antibiotic resistant bacteria across the U.S. In addition, antibiotic resistance contributes to the morbidity and mortality of healthcare-associated infections (HAI) that kill an estimated 75,000 people annually.1“The ability to provide not only rapid identification but also rapid phenotypic susceptibility ensures patients receive the most effective and appropriate therapy in a timely manner,” said James Lewis, PharmD, Infectious Diseases Clinical Pharmacy Coordinator and Adjunct Associate Professor at Oregon Health and Science University and member of the CLSI Subcommittee on Antimicrobial Susceptibility Testing. “We know each hour of inadequate antibiotic therapy increases mortality and that excessive use of broad spectrum agents drives resistance. The faster we can tailor therapy, the better things are for the patient and the potential prevention of antibiotic resistance.”Culture based identification and susceptibility systems require time consuming manual procedures, resulting in laboratory processing time that often exceeds 48 hours. With the Accelerate PhenoTest™ BC kit, labs can reduce the turnaround time by testing directly from positive blood culture samples, producing results up to 40 hours faster than conventional methods.The Accelerate PhenoTest™ BC kit is a multiplexed in vitro diagnostic test utilizing both qualitative nucleic acid fluorescence in situ hybridization (FISH) identification and quantitative antimicrobial susceptibility testing methods intended for use with the Accelerate Pheno™ system. The blood culture kit is capable of simultaneous detection and identification of multiple microbial targets followed by susceptibility testing of the appropriate detected bacterial organisms using morphokinetic cellular analysis (MCA) of individual microbial cells and colonies under the challenge of antibiotics.The Accelerate clinical study included more than 39,000 tests conducted on 1,850 samples across 13 trial sites and exceeded the requirements of the FDA for identification and antimicrobial susceptibility testing. The study showed overall sensitivity of 97.4% and specificity of 99.3% for identification. For susceptibility, overall essential and categorical agreement versus standard broth microdilution was 96.3% and 96.4% respectively.2The Accelerate PhenoTest™ BC kit includes 140 assays for both identification and susceptibility testing, of which 116 were submitted to the FDA. The kit also includes what Accelerate refers to as a “definitive” monomicrobial test indicating when a patient’s positive blood culture sample has only one targeted pathogen. In the Accelerate clinical trial the monomicrobial result had a 99.6% positive predictive value (PPV) when evaluated in combination with the Gram stain.  The monomicrobial result, matched with a Gram stain, allows microbiologists to report results without additional laboratory workup.“We are excited to offer microbiologists and treating physicians earlier intelligence about the infections they fight on a daily basis,” said Lawrence Mehren, President and CEO of Accelerate Diagnostics, Inc. “Bringing this solution to market has been a culmination of years of effort. I could not be more proud of the Accelerate team, more grateful to our clinical trial partners, or appreciative of the FDA’s guidance throughout this endeavor.”The FDA granted the de novo request from Accelerate to legally market the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for in vitro diagnostic use. The de novo classification process provides a regulatory pathway intended to expedite FDA review of novel low-to-moderate risk devices for which no predicate device exists when special and general controls demonstrate reasonable assurance of safety and effectiveness.Accelerate will discuss the de novo request granted by the FDA with investors and analysts on its preliminary earnings conference call scheduled for, Monday, February 27, 2017 at 4:15pm ET. A live audio webcast of the call will be accessible from the investor portal of the company’s website at axdx.com/investors.Visit axdx.com to get more information about the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit.References:Reports from the Centers for Disease Control and Prevention can be found at cdc.gov/hai/surveillance/ and cdc.gov/drugresistance/Overall results are based on FDA/CLSI 2016 breakpoints – see product labeling for additional detailAbout Accelerate Diagnostics, Inc.Accelerate Diagnostics, Inc. (“Accelerate Diagnostics,”) (Nasdaq:AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and healthcare-associated infections. The company's fully automated Accelerate Pheno™ system, and direct from positive blood culture Accelerate PhenoTest™ BC kit, leverage a suite of technologies to eliminate the lengthy culture and sample preparation steps required prior to testing. Using proprietary molecular identification methods and morphokinetic cellular analysis (MCA), the solution aims to reduce the time that clinicians must wait for quantitative antimicrobial susceptibility results necessary for optimal antibiotic selection, dosing, and infusion strategy, called minimum inhibitory concentrations, or MICs.The “ACCELERATE DIAGNOSTICS”, “ACCELERATE PHENO” and “ACCELERATE PHENOTEST” logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.Forward-Looking StatementsCertain of the statements made in this press release are forward looking, such as those, among others, about our projections as to when certain key business milestones may be achieved, the potential of our products or technology, the growth of the market, our estimates as to the size of our market opportunity and potential pricing, our competitive position and estimates of time reduction to results, and our future development plans and growth strategy. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned “Risk Factors” in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 9, 2016, and in any other reports that we file with the Securities and Exchange Commission from time to time. The company's forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.Investors May Contact: Laura Pierson, Accelerate Diagnostics, +1 520 365-3100 Reporters May Contact: Andrew Chasteen, Accelerate Diagnostics, +1 520 365-3100

Read more...

More Articles...



Company Information

Official Content Partners









PRIVACY POLICY

We recommend Firefox 3 (and above) and Chrome for dynamic performance.
Copyright; 2004-2017 RobinsPost (The Bird's Eye View Company) All rights reserved.
News stories from trusted sources. RobinsPost.com provides links to news sites based on their RSS feeds.
All trademarks, copyrights, videos, photos and logos are owned by respective news sources.
ROBINSPOST.COM Is Proudly Made In America. - Where Quality, Safety and Service Comes First.